Literature DB >> 26915035

Future opportunities in diabetic retinopathy research.

Thomas W Gardner1, Emily Y Chew.   

Abstract

PURPOSE OF REVIEW: The risk of vision loss from diabetic retinopathy has fallen dramatically over the past 3 decades with improvements in diabetes and blood pressure treatments, and with advances in laser surgery and intraocular drug delivery. Nevertheless, diabetes continues to be a major cause of blindness. This study summarizes the state of the art in diabetic retinopathy research and provides a perspective on opportunities for future investigations. RECENT
FINDINGS: New insights into the pathophysiology of diabetes and diabetic retinopathy will improve metabolic control. Structure-function analyses are revealing new details of diabetic retinopathy. Intraocular drug therapy provides improved visual outcomes. Together these steps will yield better means to detect and quantify vision loss, and to develop patient-specific treatments to preserve vision for persons with diabetes.
SUMMARY: Retinopathy is one of the most successfully treated complications of diabetes and will continue to be an important area of research for patients and their families.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26915035      PMCID: PMC4959271          DOI: 10.1097/MED.0000000000000238

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  63 in total

Review 1.  Diabetic retinopathy.

Authors:  David A Antonetti; Ronald Klein; Thomas W Gardner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

Review 2.  Challenges in elucidating the genetics of diabetic retinopathy.

Authors:  Jane Z Kuo; Tien Y Wong; Jerome I Rotter
Journal:  JAMA Ophthalmol       Date:  2014-01       Impact factor: 7.389

Review 3.  Glial cell regulation of neuronal activity and blood flow in the retina by release of gliotransmitters.

Authors:  Eric A Newman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

4.  Early neurodegeneration in the retina of type 2 diabetic patients.

Authors:  Hille W van Dijk; Frank D Verbraak; Pauline H B Kok; Marilette Stehouwer; Mona K Garvin; Milan Sonka; J Hans DeVries; Reinier O Schlingemann; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-14       Impact factor: 4.799

5.  Intensive diabetes therapy and ocular surgery in type 1 diabetes.

Authors:  Lloyd Paul Aiello; Wanjie Sun; Arup Das; Sapna Gangaputra; Szilard Kiss; Ronald Klein; Patricia A Cleary; John M Lachin; David M Nathan
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

6.  Advanced imaging for glaucoma study: design, baseline characteristics, and inter-site comparison.

Authors:  Phuc V Le; Xinbo Zhang; Brian A Francis; Rohit Varma; David S Greenfield; Joel S Schuman; Nils Loewen; David Huang
Journal:  Am J Ophthalmol       Date:  2014-11-08       Impact factor: 5.258

7.  Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.

Authors:  Cristina Hernández; Patricia Bogdanov; Lidia Corraliza; Marta García-Ramírez; Cristina Solà-Adell; José A Arranz; Ana I Arroba; Angela M Valverde; Rafael Simó
Journal:  Diabetes       Date:  2015-09-17       Impact factor: 9.461

8.  Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.

Authors:  John M Lachin; Paula McGee; Jerry P Palmer
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

9.  Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC.

Authors:  John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan
Journal:  Diabetes       Date:  2014-09-09       Impact factor: 9.461

10.  Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy.

Authors:  Judd M Cahoon; Ruju R Rai; Lara S Carroll; Hironori Uehara; Xiaohui Zhang; Christina L O'Neil; Reinhold J Medina; Subtrata K Das; Santosh K Muddana; Paul R Olson; Spencer Nielson; Kortnie Walker; Maggie M Flood; Wyatt B Messenger; Bonnie J Archer; Peter Barabas; David Krizaj; Christopher C Gibson; Dean Y Li; Gou Y Koh; Guangping Gao; Alan W Stitt; Balamurali K Ambati
Journal:  Diabetes       Date:  2015-09-04       Impact factor: 9.461

View more
  2 in total

1.  Effect of three-dimensional reconstruction-assisted 23G micro-invasive vitrectomy in patients with proliferative diabetic retinopathy.

Authors:  Min Fu; Xiaohe Lu; Huijun Hu; Songfu Feng; Wei Wu; Xiaoyun Ke; Xiaoping Xu; Xiaohong Chen; Huiqiao Hai
Journal:  Exp Ther Med       Date:  2017-04-13       Impact factor: 2.447

2.  Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective.

Authors:  Silvia Nanjala Walekhwa Hertzberg; Øystein K Jørstad; Beáta Éva Petrovski; Ragnheidur Bragadottir; Leif Arthur Steffensen; Morten Carstens Moe; Emily A Burger; Goran Petrovski
Journal:  Int J Environ Res Public Health       Date:  2022-10-02       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.